Table 2.

Wild or Mutated p53 Tumor and T cell Recognition

				Patient 1			Patient 2
Target	Tumor Type	Comment	CM	UTD	gp100:154 TCR	p53:264 TCR	p53:264 TCR
Controls
CM			a35	89	355	273	424
888	Melanoma	HLA-A2−	29	49	164	127	312
938	Melanoma	HLA-A2−	29	58	211	149	213
SaOS2	Osteosarcoma	A2+ / p53:264 deleted	29	66	171	572	110
NCIH522	NSCLC	A2+ / p53:264 deleted	32	39	111	730	505
HLA-A2+ wild type p53 tumor cell lines
SF539b	Glioma		42	106	537	5500	2127
HepG2	HCC		31	58	330	3869	2486
SKMEL5	Melanoma		47	67	52194	1671	610
UAcc62	Melanoma		32	62	285	2685	544
UACC257	Melanoma		41	116	82128	17717	9033
a498	RCC		35	57	534	14927	5914
HCT116	Colon Carcinoma		33	52	238	4350	3702
MCF7	Breast Carcinoma		31	56	463	8136	7646
A375	Melanoma		32	116	542	3806	864
IM9	Multiple Myleoma		32	577	15195	35638	8913
MALME-3M	Melanoma		32	117	77458	20203	9106
HLA-A2+ mutated p53 tumor cell lines
		p53 mutation
H2087	NSCLC	157 V/F	25	99	443	43103	24301
RXF393	RCC	175 R/H	30	31	593	5069	2878
OVCAR3	Ovarian Cancer	248 R/Q	28	56	198	3519	781
BT549	Breast Carcinoma	249 R/S	25	72	241	932	479
SNB75	Giloma	258 E/K	30	118	408	15001	8421
MDA-MB231	Breast Carcinoma	280 R/K	28	124	4046	23483	12497

Abbreviations: CM, Complete Media; UTD, Untransduced; TCR, T cell receptor, NSCLC, non small cell lung cancer; A2, HLA-A2; p53:264 deleted, the p53 epitope encompassing amino acids 264 to 272 is not expressed in these cell lines; HCC, hepatocellular carcinoma; RCC; renal cell carcinoma

^aValues represent IFN-γ (pg/mL) after overnight coculture, specific recognition is underlined and designated as twice background (tumor cell and complete media (CM) controls) and greater than 200 pg/mL

^bSF-539 is noted to contain wildtype p53 (O’Connor et al., 1997), however, a mutation occurring following the relevant p53_264–272 epitope at bp 1042 (deletion C) resulting in a frameshift at codon 342 and subsequent stop codon has been described in the COSMIC database (Bamford et al, 2004).